ClexBio is a biotech company creating breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with our proprietary hydrogel technology CLEX.
The CLEX technology allows hydrogel formation with, both, precise control and exceptional biocompatibility. This enables us to use microfluidic devices to form hydrogel microstructures containing delicate biological cargo such as living cells.
A. G. Håti et al, Versatile, cell and chip friendly method to gel alginate in microfluidic devices. Lab Chip (2016), 10.1039/C6LC00769D
A. G. Håti at al, Microarrays for the study of compartmentalized microorganisms in alginate microbeads and (W/O/W) double emulsions. RSC Adv. (2016), 10.1039/C6RA23945E
D. C. Bassett et al, Competitive ligand exchange of crosslinking ions for ionotropic hydrogel formation. J. Mater. Chem. B. (2016) 10.1039/C6TB01812B
K. Yamamoto et al, Local Structure of Ca2+ Alginate Hydrogels Gelled via Competitive Ligand Exchange and Measured by Small Angle X-ray Scattering. Gels (2019), 10.3390/gels5010003
We are a dedicated, globally minded team ready with experience from leading universities and biotech companies in Europe and the US. We are supported by a strong network of A-level entrepreneurs and innovators.
Armend co-invented the CLEX technology during his PhD & PostDoc in biophysics at NTNU, Harvard University, and EPFL. His research expertise is complemented by commercial experience from his previous position as Director for Product & Technology at Aker BioMarine.
Manuel holds a PhD in biomaterials science and tissue engineering from UiO. He also worked on national and international industry-driven research projects within nanomedicine as a Research Scientist at SINTEF and has experience in commercial product development.
Mia holds a PhD in Vascular Tissue Engineering from the University of Oslo. During her PhD she earned a scholarship from The Fulbright Program for a research stay at Yale University on top of research stays and exchanges at the Wake Forest Institute for Regenerative Medicine, the Università degli Studi di Milano and the University of California, Berkeley.
Tia has pursued a PhD in biomedicine at the University of Stavanger. She holds an MSc in Biological Chemistry from the University of Stavanger. Tia has worked extensively with mammalian cell culture in conventional 2D systems, spheroids, 3D, and microfluidics. On top of that, she has ample experience from SMEs to GMP labs to large medical device companies.
Madeleine supports the ClexBio team as Visiting Scientist by developing new cell-friendly biomaterial formulations for upscaled production. Her research stay is supported by a grant from Digital Life Norway. When not at ClexBio, she pursues a PhD in biotechnilogy at NTNU where she studies microbial community dynamics.
Andreas is an enthusiastic startup supporter and an expert in commercializing products within biotech and pharma. Currently, he is a Director of Global Pharma Strategy at Novartis and previously worked several years for McKinsey's pharma & biotech practice in Europe, China and the US. He holds an MBA from INSEAD and is a licensed lawyer.
Ramzi is a pharma pro with years of experience in sales, marketing, and market access. He co-founded the health-tech company Symmetryk and holds a senior position at Novartis and previously Roche. He holds an MSc from Stanford University and an MBA from INSEAD, where he teaches as an adjunct professor.
David is an ardent researcher at the interface of material science & biology. He co-invented CLEX together with Armend at NTNU. Currently, he works and teaches as a lecturer in Healthcare Technologies at the University of Birmingham. He holds a PhD in Biomedical Material Science from McGill University.
Lotte is a nanotechnology enthusiast with a passion for biotech. She directs Aker Biomarine's product and technology development, is a board member of The Life Science Cluster, and has been named among Norway's top 50 women in tech. She holds an MSc in nanotechnology from NTNU, spent 7 years with the Boston Consulting Group.
Anders is an experienced investment and business development professional with extensive experience in C-level positions from the health care and biotech industry. He is the Investment Director at Radforsk, chairman of Vaccibody, and has been heavily involved in the development of several biotech companies.